Breast MRI as an Adjunct to Mammography for Breast Cancer Screening in High-Risk Patients: Retrospective Review

被引:50
作者
Raikhlin, Antony [1 ]
Curpen, Belinda [2 ]
Warner, Ellen [3 ]
Betel, Carrie [2 ]
Wright, Barbara [2 ]
Jong, Roberta [2 ]
机构
[1] Univ Toronto, St Michaels Hosp, Dept Med Imaging, Toronto, ON, Canada
[2] Univ Toronto, Sunnybrook Hlth Sci Ctr, Breast Div, Dept Med Imaging, Toronto, ON, Canada
[3] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Oncol, Toronto, ON, Canada
关键词
BRCA1; BRCA2; breast cancer; breast MRI; high-risk screening; mammography; HIGH FAMILIAL RISK; HIGH GENETIC RISK; OVARIAN-CANCER; MUTATION CARRIERS; BRCA MUTATIONS; WOMEN; SURVEILLANCE; ULTRASOUND; AGE; THERAPY;
D O I
10.2214/AJR.13.12264
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. In July 2011, the provincial government of Ontario, Canada, approved funding for the addition of annual breast MRI to mammography screening for all women 3069 years old considered to be at high risk for breast cancer. The purpose of this study was to evaluate the diagnostic performance of screening breast MRI as compared with mammography in a population-based high-risk screening program. MATERIALS AND METHODS. A retrospective review identified 650 eligible high-risk women who underwent screening breast MRI and mammography between July 2011 and January 2013 at one institution. Results of 806 screening rounds (comprising both MRI and mammography) were reviewed. RESULTS. Malignancy was diagnosed in 13 patients (invasive cancer in nine, ductal carcinoma in situ in three [one with microinvasion], and chest wall metastasis in one). Of the 13 cancers, 12 (92.3%) were detected by MRI and four (30.8%) by mammography. In nine of these patients, the cancer was diagnosed by MRI only, resulting in an incremental cancer detection rate of 10 cancers per 1000 women screened. MRI screening had significantly higher sensitivity than mammography (92.3% vs 30.8%) but lower specificity (85.9% vs 96.8%). MRI also resulted in a higher callback rate for a 6-month follow-up study (BI-RADS category 3 assessment) than mammography (119 [14.8%] vs 13 [1.6%]) and more image-guided biopsies than mammography (95 [11.8%] vs 19 [2.4%]). CONCLUSION. MRI is a useful adjunct to mammography for screening in high-risk women, resulting in a significantly higher rate of cancer detection. However, this was found to be at the cost of more imaging and biopsies for lesions that ultimately proved to be benign.
引用
收藏
页码:889 / 897
页数:9
相关论文
共 40 条
  • [1] Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
    Antoniou, A
    Pharoah, PDP
    Narod, S
    Risch, HA
    Eyfjord, JE
    Hopper, JL
    Loman, N
    Olsson, H
    Johannsson, O
    Borg, Å
    Pasini, B
    Radice, P
    Manoukian, S
    Eccles, DM
    Tang, N
    Olah, E
    Anton-Culver, H
    Warner, E
    Lubinski, J
    Gronwald, J
    Gorski, B
    Tulinius, H
    Thorlacius, S
    Eerola, H
    Nevanlinna, H
    Syrjäkoski, K
    Kallioniemi, OP
    Thompson, D
    Evans, C
    Peto, J
    Lalloo, F
    Evans, DG
    Easton, DF
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1117 - 1130
  • [2] The BOADICEA model of genetic susceptibility to breast and ovarian cancer
    Antoniou, AC
    Pharoah, PPD
    Smith, P
    Easton, DF
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (08) : 1580 - 1590
  • [3] The pathology of inherited breast cancer
    Armes, JE
    Venter, DJ
    [J]. PATHOLOGY, 2002, 34 (04) : 309 - 314
  • [4] Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease
    Beral, V
    Bull, D
    Doll, R
    Peto, R
    Reeves, G
    [J]. LANCET, 2001, 358 (9291) : 1389 - 1399
  • [5] High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: Report from the late effects study group
    Bhatia, S
    Yasui, Y
    Robison, LL
    Birch, JM
    Bogue, MK
    Diller, L
    DeLaat, C
    Fossati-Bellani, F
    Morgan, E
    Oberlin, O
    Reaman, G
    Ruymann, FB
    Tersak, J
    Meadows, AT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4386 - 4394
  • [6] Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
    Brekelmans, CTM
    Seynaeve, C
    Bartels, CCM
    Tilanus-Linthorst, MMA
    Meijers-Heijboer, EJ
    Crepin, CMG
    van Geel, AN
    Menke, M
    Verhoog, LC
    van den Ouweland, A
    Obdeijn, IM
    Klijn, JGM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) : 924 - 930
  • [7] Carney PA, 2003, ANN INTERN MED, V138, P168, DOI 10.7326/0003-4819-138-3-200302040-00008
  • [8] Mammography in Asian patients with BRCA1 mutations
    Chang, J
    Yang, WT
    Choo, HF
    [J]. LANCET, 1999, 353 (9169) : 2070 - 2071
  • [9] THE LIFETIME RISK OF DEVELOPING BREAST-CANCER
    FEUER, EJ
    WUN, LM
    BORING, CC
    FLANDERS, WD
    TIMMEL, MJ
    TONG, T
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (11) : 892 - 897
  • [10] Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
    Ford, D
    Easton, DF
    Stratton, M
    Narod, S
    Goldgar, D
    Devilee, P
    Bishop, DT
    Weber, B
    Lenoir, G
    Chang-Claude, J
    Sobol, H
    Teare, MD
    Struewing, J
    Arason, A
    Scherneck, S
    Peto, J
    Rebbeck, TR
    Tonin, P
    Neuhausen, S
    Barkardottir, R
    Eyfjord, J
    Lynch, H
    Ponder, BAJ
    Gayther, SA
    Birch, JM
    Lindblom, A
    Stoppa-Lyonnet, D
    Bignon, Y
    Borg, A
    Hamann, U
    Haites, N
    Scott, RJ
    Maugard, CM
    Vasen, H
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) : 676 - 689